CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia

Clin Epigenetics. 2016 May 5:8:50. doi: 10.1186/s13148-016-0216-3. eCollection 2016.

Abstract

Background: Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative neoplasm of childhood whose clinical heterogeneity is only poorly represented by gene sequence alterations. It was previously shown that aberrant DNA methylation of distinct target genes defines a more aggressive variant of JMML, but only few significant targets are known so far. To get a broader picture of disturbed CpG methylation patterns in JMML, we carried out a methylation screen of 34 candidate genes in 45 patients using quantitative mass spectrometry.

Findings: Five of 34 candidate genes analyzed showed recurrent hypermethylation in JMML. cAMP-responsive element-binding protein-binding protein (CREBBP) was the most frequent target of epigenetic modification (77 % of cases). However, no pathogenic mutations of CREBBP were identified in a genetic analysis of 64 patients. CREBBP hypermethylation correlated with clinical parameters known to predict poor outcome.

Conclusions: This study supports the relevance of epigenetic aberrations in JMML pathophysiology. Our data confirm that DNA hypermethylation in JMML is highly target-specific and associated with higher-risk features. These findings encourage the development of prognostic markers based on epigenetic alterations, which will be helpful in the difficult clinical management of this heterogeneous disease.

Keywords: CREBBP; DNA methylation; Epigenetics; Juvenile myelomonocytic leukemia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CREB-Binding Protein / genetics*
  • CpG Islands
  • DNA Methylation*
  • Epigenesis, Genetic
  • Humans
  • Leukemia, Myelomonocytic, Juvenile / genetics*
  • Leukemia, Myelomonocytic, Juvenile / pathology*
  • Mass Spectrometry / methods
  • Prognosis

Substances

  • CREB-Binding Protein
  • CREBBP protein, human